HS627 + trastuzumab + docetaxel

This is a **combination regimen** comprised of *HS627*, *trastuzumab*, and *docetaxel* for the treatment of HER2-positive breast cancer. HS627 is a biosimilar of pertuzumab developed by BioRay Pharmaceutical and Hisun BioRay. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), inhibiting its signaling and leading to growth arrest and apoptosis of HER2-overexpressing tumor cells. Docetaxel is a chemotherapeutic agent (taxane class) that disrupts microtubule function, leading to cell cycle arrest and apoptosis. This triple regimen is studied as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer in ongoing Phase III trials, aiming to improve pathological complete response rates compared to existing regimens[1][3][4].